前立腺癌に対するEstramustine phosphateの臨床効果に関する検討

Abstract

This study consisted of clinical evaluation of estramustine phosphate for the patients of prostatic carcinoma with or without the previous treatment. The results were as follows. 1. In seven patients without previous treatment, five showed the objective effect, one the subjective, and one no response when evaluated on three months after treatment. The objective effect in these five patients continued from six to nineteen months. One patient in these, however, escaped from the treatment on the seventeenth month. One patient with subjective and one with no effect died of prostatic carcinoma within twelve months after treatment. 2. In six patients who had been resistant to or had relapsed from the previous treatment, there were four who showed the objective effect, when evaluated on three months after treatment. The objective effect in three patients lasted from twelve to twenty six months. Two patients with no effect evaluated on three months after treatment, died of prostatic carcinoma within six months after start of this study. 3. Side effects were evaluated in seventeen patients. All had the gastrointestinal disturbances. Two patients could not continue to have the treatment because of their severities. We also noticed the anemia as the side effect of bone marrow suppression to be intensified in patients with the marked bon emetastases. This was believed to have resulted from the alkylating action of estramustine phosphate. We had no side effects on breasts because of irradiation to them. 4. We concluded from this clinical study, first, oral estramustine phosphate showed good clinical effect in patients of prostatic carcinoma without previous treatment. Second, this drug was less effective for the patients with the previous treatment than for those without the previous one. Thirty or forty percent in these patients were supposed to have clinically objective effect. Because of the limited effect of other form of treatment we believed estramustine phosphate to be the first choice of treatment for carcinoma of the prostate, considering its minimal side effect.